Tongmai Jiangtang Capsule for Cardiovascular Clinical Outcomes in High-Risk Metabolic Syndrome Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

PHASE3

Total Enrollment

530 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-04-24

Study Completion Date

2028-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Conduct a large-sample, multicenter, superiority, double-blind, randomized controlled clinical trial to verify the efficacy of TJC in reducing the risk of cardiovascular and cerebrovascular events in patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS).
2. Further construct an evaluation system for the long-term cardiovascular and cerebrovascular benefits of traditional Chinese medicine in regulating glucose and lipid metabolism through the evaluative study of the cardiovascular and cerebrovascular benefits of TJC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study

NCT07121088

Ischemic Cerebral Infarction Diabetes Mellitus

NOT_YET_RECRUITING PHASE4

Curative Efficacy of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM

NCT02334969

Ischemic Stroke

COMPLETED PHASE4

Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke

NCT00710164

Acute Ischemic Stroke

UNKNOWN PHASE2/PHASE3

Evidence-based Evaluation of TCM Key Syndrome Differentiation and Treatment for Acute Ischemic Stroke

NCT04199455

Ischemic Stroke

UNKNOWN PHASE4

Risk Assessment Model for Ischemic Stroke Endpoint Events

NCT03174535

Ischemic Stroke

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Metabolic Syndrome Cardiovascular Disease (CKD) Cerebrovascular Disease Qi Deficiency and Blood Stasis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental Group (Tongmai Jiangtang Capsule Group)

Participants in this Arm will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.

Dosage: Three capsules, three times daily (tid), taken orally. Duration: The intervention period is 26 weeks, followed by a 26-week follow-up. Objective: This Arm aims to evaluate the efficacy of TJC in reducing cardiovascular and cerebrovascular event risks in patients with metabolic syndrome at high cardiovascular risk (HCR-MS).

Participants will adhere to the study protocol, attending regular visits and examinations to assess efficacy and safety.

Group Type EXPERIMENTAL

Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.

Intervention Type DRUG

Intervention Agent: The study employs Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine compound formulated based on TCM theory. It has the functions of Nourishing Yin, clearing heat and activating blood circulation, and can comprehensively regulate glucose and lipid metabolism as well as improve cardiovascular and cerebrovascular functions.

Intervention Population: The study focuses on patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS) who meet the TCM criteria for "Qi-deficiency and Blood Stasis syndrome," reflecting personalized and precision intervention.

Intervention Design: A long-term study design with 26 weeks of intervention followed by 26 weeks of follow-up is adopted to comprehensively assess the short-term efficacy and long-term cardiovascular benefits of TJC.

Control Design: The study employs a double-blind, randomized, placebo-controlled method.

Control Group (Placebo Group)

Participants in this Arm will receive a placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC, in addition to standard treatment.

Dosage: Three placebo capsules, three times daily (tid), taken orally. Duration: The intervention period is 26 weeks, followed by a 26-week follow-up. Objective: This Arm serves as a control to compare the efficacy of TJC against a placebo.

Participants will adhere to the study protocol, attending regular visits and examinations to assess the efficacy and safety of the placebo.

Group Type PLACEBO_COMPARATOR

A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC

Intervention Type DRUG

Participants in this Arm will receive a placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC, in addition to standard treatment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Participants will receive Tongmai Jiangtang Capsule (TJC) in addition to standard treatment.

Intervention Agent: The study employs Tongmai Jiangtang Capsule (TJC), a traditional Chinese medicine compound formulated based on TCM theory. It has the functions of Nourishing Yin, clearing heat and activating blood circulation, and can comprehensively regulate glucose and lipid metabolism as well as improve cardiovascular and cerebrovascular functions.

Intervention Population: The study focuses on patients with metabolic syndrome at high cardiovascular and cerebrovascular risk (HCR-MS) who meet the TCM criteria for "Qi-deficiency and Blood Stasis syndrome," reflecting personalized and precision intervention.

Intervention Design: A long-term study design with 26 weeks of intervention followed by 26 weeks of follow-up is adopted to comprehensively assess the short-term efficacy and long-term cardiovascular benefits of TJC.

Control Design: The study employs a double-blind, randomized, placebo-controlled method.

Intervention Type DRUG

A placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC

Participants in this Arm will receive a placebo capsule that is identical in appearance, size, color, formulation, weight, taste, and smell to TJC, in addition to standard treatment.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: Participants must be aged ≥65 years.
* Participants must meet the diagnostic criteria for metabolic syndrome according to the 2020 Chinese Type 2 Diabetes Prevention Guidelines, which includes at least three of the following criteria:①Central obesity: Waist circumference ≥90 cm for men, ≥85 cm for women.②Hyperglycemia: Fasting blood glucose ≥6.1 mmol/L or 2-hour post-load glucose ≥7.8 mmol/L, or a confirmed diagnosis of diabetes with ongoing treatment.③Hypertension: Blood pressure ≥130/85 mmHg or a confirmed diagnosis of hypertension with ongoing treatment.④Elevated triglycerides (TG): ⑤Fasting TG ≥1.70 mmol/L.

Low HDL cholesterol: Fasting HDL-C \<1.04 mmol/L.

* Participants must meet the criteria for "Qi-deficiency and Blood Stasis" syndrome, which includes specific symptoms and signs such as fatigue, shortness of breath, stabbing pain, ecchymosis, and a tongue with purple discoloration or petechiae.
* High Cardiovascular Risk: Participants must have at least one of the following:

* History of myocardial infarction.

* History of stroke or transient ischemic attack. ③History of coronary, carotid, or peripheral artery revascularization.

* Coronary, carotid, or lower limb artery stenosis \>50%. ⑤Positive exercise stress test or documented symptomatic coronary heart disease, or unstable angina with ECG changes.

* Chronic heart failure (NYHA Class II-III). ⑦Chronic kidney disease (eGFR \<60 ml/min/1.73m²).

Exclusion Criteria

* Secondary Abnormalities: Secondary abnormalities in lipids, blood pressure, or blood glucose.
* Type 1 Diabetes: Participants with Type 1 diabetes mellitus.
* Special Populations: Pregnant or breastfeeding individuals, or those with a history of allergy to the study medication.
* Recent Acute Events: Acute coronary or cerebrovascular events within the past 14 days.
* Upcoming Revascularization: Planned coronary, carotid, or peripheral artery revascularization.
* Severe Heart Failure: Chronic heart failure (NYHA Class IV).
* End-Stage Liver Disease: Participants with end-stage liver disease.
* Solid Organ Transplantation: History of solid organ transplantation or awaiting solid organ transplantation.
* Malignant Tumors: Participants with a history of malignant tumors.
* Other Serious Conditions: Any other serious medical conditions that may interfere with the study or pose a risk to the participant.

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No